Arch Oncology

Arch Oncology, Inc. is a clinical-stage company headquartered in Brisbane, California. Currently, the company employs 7 individuals. Arch Oncology focuses on the discovery and development of antibody therapies for patients with solid tumors and hematologic malignancies. Their lead product candidate, AO-176, is in Phase 1/2 clinical trials for the treatment of select solid tumors and multiple myeloma, both as a monotherapy and in combination with standard therapies. The company's next-generation anti-CD47 antibodies are designed to provide improved safety and efficacy compared to existing agents in this class. AO-176 works through multiple mechanisms, including blocking the "don't eat me" signal for macrophages, directly killing tumor cells, and inducing Immunogenic Cell Death. Notably, AO-176 preferentially binds to CD47 on tumor cells, rather than normal cells, and exhibits stronger binding in the low pH environment of the tumor microenvironment. Arch Oncology can be reached through their website at archoncology.com.